Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL25326318 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9CA3 | |
| Trifluoroacetic Acid SCHEMBL466686 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9CA3 | |
| Trifluoroacetic Acid SCHEMBL30260008 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9CA3 | |
| Hydroquinone SCHEMBL27638163 | 0.89 | CA2 (0.50) | CA12CA1CA2CA9CA3 | |
| Phenol SCHEMBL27815365 | 0.87 | CA12 (0.55) | CA12CA1CA2CA9CA3 | |
| Phenol SCHEMBL81020 | 0.87 | CA12 (0.55) | CA12CA1CA2CA9CA3 | |
| Trifluoroacetic Acid SCHEMBL5571447 | 0.87 | CA12 (0.44) | CA12CA1CA2CA9CA3 | |
| Resorcinol SCHEMBL11567030 | 0.85 | ALDH1A1 (0.57) | CA12CA1CA2CA9CA14 | |
| Trifluoroacetamide SCHEMBL2766693 | 0.85 | TDP1 (0.52) | CA12CA1CA2CA9CA3 | |
| Catechol SCHEMBL9330300 | 0.84 | CA2 (0.53) | CA12CA1CA2CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4182313-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-1687311-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049620-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | CA12 3794/4885CA1 2225/4885CA2 3455/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | CA12 3794/4885CA1 2225/4885CA2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.